{{item.date}}
{{subItem.title}}
{{subItem.subtitle}}




北京大学未来技术学院 School of Future Technology, Peking University
教授 Professor
罗金才,北京大学未来技术学院教授,分子医学研究所血管生物学研究室主任(PI),兼任北京大学国家生物医学成像科学中心科学项目部主任,博士生导师。1999年在日本东京大学医科学研究所获得博士学位,其后在美国哈佛大学医学院等院校从事细胞信号转导博士后研究。2005年加入北京大学分子医学研究所,2008年起独立主持血管生物学研究室工作。长期致力于血管细胞分子生物学的基础及转化研究,主要方向包括血管损伤与修复,内皮细胞分泌与血栓、炎症,淋巴管新生与抗肿瘤免疫等。主要成果包括揭示血管新生新型信号通路,发现内皮细胞分泌新现象、调控新基因及其与人类疾病的关联性,发现脑膜淋巴管介导抗肿瘤免疫及其应用价值。近来在学术杂志PNAS, Cell Research, Nature Communications, Blood等以通讯作者发表学术论文多篇,并受邀为Trends in Cell Biology, Cardiovascular Research等杂志撰写述评。现任多家国际杂志副主编(Cancer Science, Frontiers in Physiology)及编辑(Angiogenesis, Cells)。目前担任中国生理学会血栓与止血专业委员会副主任委员、循环生理专业委员会委员,中国病理生理学会血管医学专业委员会委员等。北京大学/拜尔学者奖获得者(2018)。
Luo Jincai, Professor of School of Future Technology, Peking University, Director of Vascular Biology Research Office, Institute of Molecular Medicine (PI), Director of Science Program and doctoral Supervisor of National Biomedical Imaging Science Center of Peking University. He received his doctorate from the Institute of Medical Sciences, University of Tokyo, Japan in 1999, and then engaged in postdoctoral research in cellular signal transduction at Harvard Medical School and other universities in the United States. He joined the Institute of Molecular Medicine of Peking University in 2005 and independently presided over the work of the laboratory of vascular biology since 2008. Long-term commitment to the basis of vascular cell molecular biology and transformation research, including vascular injury and repair, endothelial cell secretion and thrombus, inflammation, lymphangiogenesis and anti-tumor immunity and so on. The main achievements include revealing new angiogenesis signal pathways, discovering new phenomena secreted by endothelial cells, regulating new genes and their association with human diseases, and finding anti-tumor immunity mediated by meningeal lymphatic vessels and its application value. Recently, he has published many academic papers as correspondent authors in academic magazines PNAS, Cell Research, Nature Communications, Blood, etc., and has been invited to write reviews for Trends in Cell Biology, Cardiovascular Research and other magazines. He is currently deputy editor-in-chief (Cancer Science, Frontiers in Physiology) and editor (Angiogenesis, Cells) of several international magazines. At present, he is the vice chairman of the Thrombosis and Hemostasis Committee of the Chinese physiological Society, a member of the Circulation Physiology Committee, and a member of the Vascular Medicine Committee of the Chinese Pathophysiology Society. Winner of Peking University / Bayer Scholars Award (2018).
报告题目:
多模态跨尺度生物医学成像设施
Introduction to multimodal cross-scale biomedical imaging facility
报告摘要:
座落在北京怀柔的多模态、跨尺度生物医学成像设施(以下简称“成像设施”)是 “十三五”国家重大科技基础设施之一,具备世界先进的医学成像、活体细胞结构功能成像以及高分辨分子成像系统,可以对重要器官与系统进行全观(宏观、介观、微观)成像,深度解析、刻画从分子到生命体各层次结构和功能的全景图。成像设施由北京大学国家生物医学成像科学中心(NBIC)负责建设,即将进入试运行阶段。为了充分发挥成像设施这一国家级公共平台对国家生命科学领域重大研究的支撑作用,探索有组织科研的研究新范式,NBIC自2022年10月起面向全国科技界征集早鸟项目建议,包括科学计划、托举计划、课题合作三类。对于遴选通过的项目,NBIC将提供成建制、全方位、全周期的合作攻关,包括技术改造与研发的定制化以及数据分析软件研发等。目前在研的早鸟项目已有10余个,早鸟项目2.0征集活动正在进行中。
The Multi-Modal, Cross-Scale Biomedical Imaging Facility (hereinafter referred to as "Imaging Facility"), located in Huairou, Beijing, is one of the national major scientific and technological infrastructures of the 13th Five-Year Plan, and is equipped with the world's advanced medical imaging, in vivo cell structure and function imaging, and high-resolution The facility is equipped with the world's most advanced medical imaging, in vivo cell structure-function imaging, and high-resolution molecular imaging systems, which can perform whole-view (macroscopic, mesoscopic, and microscopic) imaging of vital organs and systems, and deeply analyze and portray a panorama of structure and function at all levels from molecules to living bodies. The National Biomedical Imaging Center (NBIC) of Peking University is responsible for the construction of the imaging facility, which is about to enter the trial operation stage. In order to give full play to the imaging facility as a national public platform to support major national research in the life sciences and explore a new research paradigm of organized scientific research, NBIC has been soliciting early bird project proposals from October 2022 for the national science and technology community, including three categories of scientific programs, tortuous programs, and subject collaborations. For projects selected and approved, NBIC will provide establishment, all-round and full-cycle cooperation and research, including customization of technology transformation and R&D as well as data analysis software development. At present, there are more than 10 early bird projects under research, and the call for early bird projects 2.0 is in progress.
{{subItem.subtitle}}
罗金才,北京大学未来技术学院教授,分子医学研究所血管生物学研究室主任(PI),兼任北京大学国家生物医学成像科学中心科学项目部主任,博士生导师。1999年在日本东京大学医科学研究所获得博士学位,其后在美国哈佛大学医学院等院校从事细胞信号转导博士后研究。2005年加入北京大学分子医学研究所,2008年起独立主持血管生物学研究室工作。长期致力于血管细胞分子生物学的基础及转化研究,主要方向包括血管损伤与修复,内皮细胞分泌与血栓、炎症,淋巴管新生与抗肿瘤免疫等。主要成果包括揭示血管新生新型信号通路,发现内皮细胞分泌新现象、调控新基因及其与人类疾病的关联性,发现脑膜淋巴管介导抗肿瘤免疫及其应用价值。近来在学术杂志PNAS, Cell Research, Nature Communications, Blood等以通讯作者发表学术论文多篇,并受邀为Trends in Cell Biology, Cardiovascular Research等杂志撰写述评。现任多家国际杂志副主编(Cancer Science, Frontiers in Physiology)及编辑(Angiogenesis, Cells)。目前担任中国生理学会血栓与止血专业委员会副主任委员、循环生理专业委员会委员,中国病理生理学会血管医学专业委员会委员等。北京大学/拜尔学者奖获得者(2018)。
Luo Jincai, Professor of School of Future Technology, Peking University, Director of Vascular Biology Research Office, Institute of Molecular Medicine (PI), Director of Science Program and doctoral Supervisor of National Biomedical Imaging Science Center of Peking University. He received his doctorate from the Institute of Medical Sciences, University of Tokyo, Japan in 1999, and then engaged in postdoctoral research in cellular signal transduction at Harvard Medical School and other universities in the United States. He joined the Institute of Molecular Medicine of Peking University in 2005 and independently presided over the work of the laboratory of vascular biology since 2008. Long-term commitment to the basis of vascular cell molecular biology and transformation research, including vascular injury and repair, endothelial cell secretion and thrombus, inflammation, lymphangiogenesis and anti-tumor immunity and so on. The main achievements include revealing new angiogenesis signal pathways, discovering new phenomena secreted by endothelial cells, regulating new genes and their association with human diseases, and finding anti-tumor immunity mediated by meningeal lymphatic vessels and its application value. Recently, he has published many academic papers as correspondent authors in academic magazines PNAS, Cell Research, Nature Communications, Blood, etc., and has been invited to write reviews for Trends in Cell Biology, Cardiovascular Research and other magazines. He is currently deputy editor-in-chief (Cancer Science, Frontiers in Physiology) and editor (Angiogenesis, Cells) of several international magazines. At present, he is the vice chairman of the Thrombosis and Hemostasis Committee of the Chinese physiological Society, a member of the Circulation Physiology Committee, and a member of the Vascular Medicine Committee of the Chinese Pathophysiology Society. Winner of Peking University / Bayer Scholars Award (2018).
报告题目:
多模态跨尺度生物医学成像设施
Introduction to multimodal cross-scale biomedical imaging facility
报告摘要:
座落在北京怀柔的多模态、跨尺度生物医学成像设施(以下简称“成像设施”)是 “十三五”国家重大科技基础设施之一,具备世界先进的医学成像、活体细胞结构功能成像以及高分辨分子成像系统,可以对重要器官与系统进行全观(宏观、介观、微观)成像,深度解析、刻画从分子到生命体各层次结构和功能的全景图。成像设施由北京大学国家生物医学成像科学中心(NBIC)负责建设,即将进入试运行阶段。为了充分发挥成像设施这一国家级公共平台对国家生命科学领域重大研究的支撑作用,探索有组织科研的研究新范式,NBIC自2022年10月起面向全国科技界征集早鸟项目建议,包括科学计划、托举计划、课题合作三类。对于遴选通过的项目,NBIC将提供成建制、全方位、全周期的合作攻关,包括技术改造与研发的定制化以及数据分析软件研发等。目前在研的早鸟项目已有10余个,早鸟项目2.0征集活动正在进行中。
The Multi-Modal, Cross-Scale Biomedical Imaging Facility (hereinafter referred to as "Imaging Facility"), located in Huairou, Beijing, is one of the national major scientific and technological infrastructures of the 13th Five-Year Plan, and is equipped with the world's advanced medical imaging, in vivo cell structure and function imaging, and high-resolution The facility is equipped with the world's most advanced medical imaging, in vivo cell structure-function imaging, and high-resolution molecular imaging systems, which can perform whole-view (macroscopic, mesoscopic, and microscopic) imaging of vital organs and systems, and deeply analyze and portray a panorama of structure and function at all levels from molecules to living bodies. The National Biomedical Imaging Center (NBIC) of Peking University is responsible for the construction of the imaging facility, which is about to enter the trial operation stage. In order to give full play to the imaging facility as a national public platform to support major national research in the life sciences and explore a new research paradigm of organized scientific research, NBIC has been soliciting early bird project proposals from October 2022 for the national science and technology community, including three categories of scientific programs, tortuous programs, and subject collaborations. For projects selected and approved, NBIC will provide establishment, all-round and full-cycle cooperation and research, including customization of technology transformation and R&D as well as data analysis software development. At present, there are more than 10 early bird projects under research, and the call for early bird projects 2.0 is in progress.